Honokiol in glioblastoma recurrence: a case report

Glioblastoma is the most common and aggressive primary tumor in the central nervous system. There is no standard of care for patients with recurrent GBM. Honokiol is a pleiotropic lignan and has the potential to be a potent and safe anticancer agent in human GBM when it is encapsulated by liposomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ce, Cai, Zehao, Huang, Yue, Liu, Xinrui, Liu, Xing, Chen, Feng, Li, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324972/
https://www.ncbi.nlm.nih.gov/pubmed/37426439
http://dx.doi.org/10.3389/fneur.2023.1172860
Descripción
Sumario:Glioblastoma is the most common and aggressive primary tumor in the central nervous system. There is no standard of care for patients with recurrent GBM. Honokiol is a pleiotropic lignan and has the potential to be a potent and safe anticancer agent in human GBM when it is encapsulated by liposomes. We report an efficient and safe response to three phases of treatment with liposomal honokiol in a patient with recurrent glioblastoma.

Ejemplares similares